Combination of HER2-targeted antibodies (Trastuzumab plus Pertuzumab) is effective against HER2 amplified ovarian cancer xenograft models

S. P. Langdon, A. H. Sims, D. J. Harrison

Research output: Contribution to journalAbstractpeer-review

Original languageEnglish
Pages (from-to)25
Number of pages1
JournalJournal of Pathology
Publication statusPublished - Sept 2013
Event7th Joint Meeting of the British-Division of the International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland - , United Kingdom
Duration: 18 Jun 201321 Jun 2013

Cite this